UPDATE: Citi Upgrades Eli Lilly (LLY) to Buy
Tweet
Share
E-mailGet Alerts LLY Hot Sheet
Price: $1,149.36 -0.88%
Rating Summary:
30 Buy, 5 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 7 | New: 5
Rating Summary:
30 Buy, 5 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 7 | New: 5
Join SI Premium – FREE
(Updated - April 29, 2015 9:58 AM EDT)
Citi upgraded Eli Lilly (NYSE: LLY) from Neutral to Buy with a price target of $100. Analysts raised evacetrapib risk peak sales estimates from $1 billion to $3.8 billion. The change follows Merck (NYSE: MRK) IMPROVE-IT data that showed its Vytorin validates cardio benefit of lowering LDL cholesterol with a non-statin agent.
For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.
Shares of Eli Lilly closed at $71.18 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Argan (AGX) to Buy
- Asana (ASAN) PT Raised to $9 at DA Davidson, Neutral Rating Maintained
- Mama’s Creations (MAMA) PT Lowered to $22 at DA Davidson Following Q2 Beat
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Hot Upgrades, UpgradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
